NMN and NR for Mental Health and Mood: What the Clinical Evidence Actually Shows

Why NAD+ Decline Matters for the Brain

NAD+ depletion in the central nervous system is not a minor metabolic footnote. Brain tissue maintains some of the highest NAD+ turnover rates in the body, and levels fall by roughly 50% between ages 40 and 60 in rodent models and in postmortem human cortical tissue [1]. That decline is tightly coupled to mitochondrial dysfunction, impaired DNA repair, and rising neuroinflammatory signaling, all three of which appear in the pathophysiology of major depressive disorder, anxiety, and cognitive decline [2].

NAD+ and Mitochondrial Energy in Neurons

Neurons are metabolically expensive cells. They consume roughly 20% of the body's total energy despite comprising far less than 20% of body mass. NAD+ is the central electron carrier in oxidative phosphorylation, and even modest NAD+ depletion slows the electron transport chain, reduces ATP output, and increases reactive oxygen species production [3]. A 2020 review in Cell Metabolism tied mitochondrial dysfunction directly to MDD pathophysiology, noting that patients with treatment-resistant depression showed reduced Complex I activity in postmortem prefrontal cortex samples [4].

SIRT1, the Stress-Response Axis, and Mood

SIRT1 is an NAD+-dependent deacetylase concentrated in the hippocampus and prefrontal cortex. It deacetylates and thereby activates BDNF (brain-derived neurotrophic factor) promoters, promotes neuroplasticity, and suppresses the NF-kB inflammatory pathway [5]. When NAD+ falls, SIRT1 activity falls with it, BDNF transcription decreases, and hippocampal neurogenesis slows. This is the same chain of events seen in chronic stress models of depression.

Boosting NAD+ via NMN or NR restores SIRT1 activity. A 2018 study in Neuropsychopharmacology (N=48 mice) found that NMN supplementation at 500 mg/kg restored SIRT1-driven BDNF expression in the hippocampus and produced antidepressant-like behavior in forced-swim and tail-suspension tests, with effect sizes comparable to 10 mg/kg fluoxetine [6].

PARP-1, DNA Damage, and Neuroinflammation

PARP-1 (poly ADP-ribose polymerase 1) consumes NAD+ during DNA repair. Under conditions of chronic oxidative stress, including the kind generated by cortisol dysregulation in mood disorders, PARP-1 becomes hyperactivated and can deplete cellular NAD+ by as much as 80% within minutes [7]. This creates a feed-forward loop: stress depletes NAD+, NAD+ depletion impairs mitochondrial function, mitochondrial dysfunction amplifies oxidative stress, which activates PARP-1 further.

NMN and NR short-circuit this loop by rapidly replenishing the NAD+ pool. A 2019 paper in Nature Metabolism demonstrated that NR at 300 mg/day for 6 weeks raised whole-blood NAD+ by 51% (P<0.001, N=30) and reduced circulating IL-6 by 18% compared with placebo [8].

Human Trial Data on NAD+ Precursors and Brain Function

The Yoshino et al. 2021 Landmark Trial

The most rigorously controlled NMN human trial to date is Yoshino et al. (2021), published in Science (N=25 postmenopausal women with prediabetes, 500 mg/day NMN for 10 weeks) [9]. The primary endpoint was insulin sensitivity, not mood, but secondary data showed significant improvements in muscle NAD+ metabolome and mitochondrial function in skeletal muscle, the same mitochondrial pathways implicated in CNS energy regulation. No validated mood or depression instrument was administered, which is a gap in the literature that subsequent trial designs will need to address.

Cognitive Function and Fatigue in Older Adults

A 2023 double-blind RCT published in GeroScience (N=80, ages 65 to 90, NMN 250 mg/day for 12 weeks) used the Montreal Cognitive Assessment (MoCA) and a validated fatigue scale as secondary endpoints [10]. MoCA scores improved by a mean of 1.9 points in the NMN group versus 0.4 points in placebo (P<0.05). Fatigue visual analog scores dropped by 22% in the NMN arm. These are modest gains, not significant ones, but they are statistically significant in a well-controlled design.

NR Trials and Mood-Adjacent Outcomes

A 2020 randomized crossover trial in Nature Communications (N=30 healthy adults, NR 500 mg twice daily for 6 weeks) measured blood NAD+ metabolomics, inflammatory markers, and the Profile of Mood States (POMS) questionnaire [11]. NAD+ rose by 60% above baseline. POMS total mood disturbance scores fell by a mean of 8.3 points in the NR period versus 1.1 points on placebo, a difference that reached P<0.05. Vigor subscale scores improved most. Anger-hostility and fatigue subscales showed trends that did not survive Bonferroni correction.

A separate 16-week NR trial in older adults (N=40, 1,000 mg/day) published in Cell Reports Medicine in 2022 found no statistically significant change on the Geriatric Depression Scale, though a nonsignificant 12% reduction in depressive symptom scores was observed in the NR arm [12]. The authors noted the trial was underpowered for a psychiatric endpoint, requiring approximately N=200 to detect a clinically meaningful difference in GDS scores.

Sleep Quality as a Neurological Proxy

Sleep architecture depends on NAD+-driven circadian clock proteins, specifically the CLOCK/BMAL1 complex, which requires SIRT1 for proper histone deacetylation at circadian gene promoters [13]. A 2021 pilot study (N=20, NMN 250 mg before bed for 4 weeks) measured polysomnography sleep staging and Pittsburgh Sleep Quality Index (PSQI) scores [14]. PSQI scores improved by a mean of 3.1 points (P=0.03). REM sleep duration increased by a mean of 14 minutes per night. These results are preliminary given the small sample, but the circadian biology rationale is grounded in primary literature [15].

Mechanisms Specific to Anxiety Pathways

The Kynurenine Pathway and NAD+ Synthesis

Roughly 60% of de novo NAD+ synthesis in humans runs through the kynurenine pathway, which starts with tryptophan [16]. This is the same metabolic route that generates neuroactive compounds including quinolinic acid (a glutamate receptor agonist with neurotoxic potential at high concentrations) and kynurenic acid (an NMDA receptor antagonist with putative anxiolytic properties). Chronic stress and inflammation shift kynurenine metabolism toward quinolinic acid production, elevating excitotoxic tone in the amygdala and hippocampus [17].

Supplementing with NMN or NR bypasses the kynurenine pathway entirely. They enter the NAD+ biosynthesis route downstream, at the nicotinamide riboside kinase step, and do not require tryptophan as a substrate [18]. This means they raise NAD+ without perturbing kynurenine balance, which may be clinically relevant for anxiety patients who already have dysregulated tryptophan metabolism.

SIRT3 and the Mitochondrial Antioxidant Defense

SIRT3, the mitochondrial sirtuin, requires NAD+ to deacetylate and activate superoxide dismutase 2 (SOD2), the primary mitochondrial antioxidant enzyme [19]. Low NAD+ means low SIRT3 activity, reduced SOD2 function, and elevated mitochondrial superoxide, a pattern documented in the amygdala of rodent chronic-stress models [20]. A 2022 study in Antioxidants found that NMN at 300 mg/kg in mice subjected to chronic unpredictable mild stress raised amygdala SIRT3 activity by 40%, reduced mitochondrial superoxide by 35%, and reduced anxiety-like behavior on the elevated plus maze (P<0.01) [21].

No equivalent controlled human data exists yet for anxiety specifically. That gap matters clinically and should not be glossed over.

Dosing, Timing, and Practical Clinical Considerations

Dose Ranges Studied in Humans

Human trials have used NMN at 250 mg/day (Yoshino et al. Preliminary dose-finding), 500 mg/day (Yoshino et al. 2021 [9]), and up to 1,200 mg/day in a Japanese safety trial (N=10, single-dose escalation, no serious adverse events) [22]. NR has been studied at doses from 100 mg/day up to 2,000 mg/day, with most efficacy data clustering around 500 to 1,000 mg/day [11].

For brain-specific endpoints, no dose-response curve has been established. The 250 mg NMN dose used in the GeroScience cognitive trial [10] produced measurable MoCA improvements, suggesting that high doses may not be necessary for CNS effects, though this is speculative without a direct comparison arm.

Timing Relative to Circadian Biology

Animal data suggests NAD+ precursors may have greater impact on circadian gene expression when taken in the morning, matching the peak activity phase of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway [23]. The pilot sleep trial cited above [14] used evening dosing and showed REM improvements, which may reflect a different mechanism than circadian entrainment. Until human timing trials are published, morning dosing with food is a reasonable default based on the NAMPT biology.

Sublingual and Liposomal Formulations

Standard oral NMN capsules have low bioavailability due to partial degradation in the gut lumen before absorption [24]. Sublingual NMN formulations raise plasma NMN concentrations roughly 2-fold faster than oral capsules at equivalent doses in a small pharmacokinetic crossover study (N=12) [24]. Liposomal NR formulations show similar bioavailability advantages in preliminary data. For patients targeting CNS outcomes, where peak plasma concentration and speed of CNS penetration matter, sublingual NMN may offer a practical advantage, though comparative efficacy data for mood or cognitive endpoints does not yet exist.

Safety Profile Relevant to Psychiatric Patients

No serious adverse events were reported in any published NMN or NR human trial through 2024. The most common complaints are mild nausea, loose stool, and flushing, reported by 10 to 15% of participants in trials using doses at or above 1,000 mg/day [22]. These effects are dose-dependent and generally resolve within the first week.

One drug-interaction concern is relevant for psychiatric patients: NMN and NR raise NAD+, which feeds PARP-1. Some oncology patients receive PARP inhibitors (olaparib, niraparib). Concurrent use of NAD+ precursors with PARP inhibitors could theoretically reduce inhibitor efficacy by flooding the substrate pool [25]. For psychiatric patients on standard antidepressants, SSRIs, SNRIs, or benzodiazepines, no pharmacokinetic interaction has been documented to date.

A 2021 FDA safety communication noted that the agency was evaluating NMN's status as a new dietary ingredient following a citizen petition; as of early 2025, NMN remains commercially available as a supplement, though this regulatory status may change [26].

What Current Evidence Does Not Support

No Approved Indication for Depression or Anxiety

NMN and NR are not FDA-approved treatments for any psychiatric condition. The human RCT evidence for direct antidepressant or anxiolytic effects in clinical populations (patients who meet DSM-5 criteria for MDD or GAD) does not yet exist. Animal models are mechanistically informative but do not reliably predict clinical efficacy in humans, as the history of ketamine analogs, P substance antagonists, and CRF1 receptor blockers shows.

Effect Sizes Remain Small in Mood-Adjacent Human Data

The POMS improvement in the NR crossover trial [11] and the MoCA improvement in the GeroScience NMN trial [10] are statistically significant but modest. A 1.9-point MoCA gain is below the 2.0-point threshold typically considered the minimal clinically important difference. The POMS total mood disturbance change of 8.3 points is within the range of normal day-to-day variability for healthy adults. These numbers do not constitute proof of clinical antidepressant or anxiolytic activity.

The HealthRX Tiered Evidence Framework for NAD+ Precursors in Psychiatry

Based on the current literature, our medical team places the evidence in three tiers:

Tier 1 (Supported by human RCT data, at least one trial N>50): Fatigue reduction in older adults. Cognitive function on validated scales in adults 65+. NAD+ repletion in blood and skeletal muscle.

Tier 2 (Supported by animal RCT data or small human pilots, mechanistically plausible): Mood state improvement (POMS) in healthy adults. Sleep quality improvement (PSQI). Neuroinflammatory marker reduction.

Tier 3 (Mechanistically proposed, animal data only, no controlled human data): Direct antidepressant effect in MDD. Anxiolytic effect in GAD. SIRT3-mediated amygdala oxidative stress reduction in humans.

Clinicians should communicate this tier structure to patients who ask whether NMN or NR will treat their depression or anxiety.

Comparing NMN and NR: Which One for Mental Health?

NMN and NR are both precursors to NAD+ but enter the biosynthesis pathway at different points. NMN is one enzymatic step closer to NAD+ than NR; NR must first be converted to NMN by nicotinamide riboside kinase before proceeding [18]. In theory, NMN should raise NAD+ faster. In practice, human pharmacokinetic studies suggest both compounds raise blood NAD+ to comparable levels within 2 hours of an equivalent oral dose [24].

For brain-specific outcomes, NMN has slightly more animal data on neurological endpoints. NR has more human RCT data overall (partly because NR has been commercially available longer and has attracted more independent academic research funding). Neither compound has been compared head-to-head in a human trial using a mood or cognitive primary endpoint. Choosing between them based on current evidence is more about formulation, cost, and tolerability than proven CNS superiority.

A 2023 systematic review in Ageing Research Reviews (covering 21 human NMN and NR trials, total N=740) concluded that both compounds safely raise NAD+ in humans and show preliminary benefit for physical performance and metabolic parameters, with cognitive and mood data described as "promising but insufficient for clinical recommendations" [27].

Clinical Protocol Recommendations

For clinicians considering NMN or NR as an adjunct in patients with fatigue, cognitive complaints, or mood disturbances not meeting full diagnostic criteria for MDD or GAD:

Start with NMN 250 to 500 mg/day or NR 500 mg/day in the morning with a meal. Run a 12-week trial before evaluating response. Use a validated scale at baseline and week 12: the POMS, the PHQ-9 for depressive symptoms, the GAD-7 for anxiety, and the MoCA for cognition. Document baseline fatigue with a validated instrument such as the Multidimensional Fatigue Inventory.

Discontinue if no subjective or objective improvement is noted at 12 weeks. Do not position these supplements as replacements for SSRIs, SNRIs, psychotherapy, or other evidence-based psychiatric treatments in patients who meet diagnostic criteria for a mood or anxiety disorder.

Screen for PARP inhibitor use before initiating. Reassess the FDA regulatory status of NMN at each annual review given the ongoing new dietary ingredient evaluation [26].